BioScale said that the ViBE Workstation is a new productivity tool capable of performing several important BioProcess applications including Host Cell Protein assays, Protein A residual contaminant and product titer analysis, all on one platform.
ViBE enables higher quality results, faster assay development and improved process workflow with limited manual intervention when used in combination with traditional assay formats.
BioScale chief operating officer Chip Leveille said that the pharmaceutical industry is changing its emphasis from purely small molecule drugs to a blend of small molecule and protein based therapeutics.
“As more biologic drugs are introduced into the pipeline, the industry will need to retool its quality control and production processes and for this we believe BioScale’s ViBE platform is suited for the growing needs of the pharmaceutical industry to provide protein measurement within an easy-to-use workstation format,” Leveille said.
The ViBE platform enables advancements in protein research by making use of AMMP (Acoustic Membrane MicroParticle) technology, which is a mechanical integration of magnetic microparticles, a universal sensor and acoustic science delivering a proprietary, non-optical protein detection and quantitation technique with ease of methods transfer from traditional assay formats.
BioScale claimed that the ViBE Workstation is the ideal tool for reliable, unattended sample analysis including reagent additions, incubation and real-time results with walkaway operation and is well suited for a variety of applications including bioprocess engineering and manufacturing assays and biomarker discovery and development.